- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Reviva Pharmaceuticals GAAP EPS of -$0.46 misses by $0.11 | 1 | Seeking Alpha | ||
| Mi | REVIVA PHARMACEUTICALS HOLDINGS, INC. - 10-Q, Quarterly Report | 3 | SEC Filings | ||
| Mi | Reviva Pharmaceuticals: Reviva Reports First Quarter 2026 Financial Results and Recent Business Highlights | 3 | GlobeNewswire (USA) | ||
| Mi | REVIVA PHARMACEUTICALS HOLDINGS, INC. - 8-K, Current Report | 6 | SEC Filings | ||
| REVIVA PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 15.04. | Reviva Pharmaceuticals sichert sich 10 Mio. US-Dollar und verlängert finanzielle Reichweite bis Q1 2027 | 1 | Investing.com Deutsch | ||
| 15.04. | Reviva Pharmaceuticals raises $10M, extends cash runway to Q1 2027 | 1 | Investing.com | ||
| 15.04. | Reviva Pharmaceuticals: Reviva Announces Letter to Shareholders | 464 | GlobeNewswire (Europe) | CUPERTINO, Calif., April 15, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva," the "Company" "we" or "us"), a late-stage pharmaceutical company developing therapies... ► Artikel lesen | |
| 15.04. | REVIVA PHARMACEUTICALS HOLDINGS, INC. - 8-K, Current Report | - | SEC Filings | ||
| 30.03. | REVIVA PHARMACEUTICALS HOLDINGS, INC. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 30.03. | Reviva Pharmaceuticals: Reviva Reports Full Year 2025 Financial Results and Recent Business Highlights | 329 | GlobeNewswire (Europe) | - Written FDA recommendations include a second Phase 3 trial to generate additional efficacy and safety data prior to NDA submission of brilaroxazine for schizophrenia - - Current data package highlights... ► Artikel lesen | |
| 30.03. | REVIVA PHARMACEUTICALS HOLDINGS, INC. - 8-K, Current Report | - | SEC Filings | ||
| 28.03. | REVIVA PHARMACEUTICALS HOLDINGS, INC. - 10-K, Annual Report | - | SEC Filings | ||
| 25.03. | Analysts Remain Confident in Reviva Pharmaceuticals Holdings (RVPH) Amid 1-for-20 Reverse Stock Split | 2 | Insider Monkey | ||
| 25.03. | Reviva Pharmaceuticals Holdings, Inc. Announces Closing of $10 Million Public Offering | 152 | GlobeNewswire (Europe) | CUPERTINO, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that... ► Artikel lesen | |
| 23.03. | Reviva Pharmaceuticals raises $10 million in public offering | 1 | Investing.com | ||
| 23.03. | Reviva Pharmaceuticals schließt Kapitalerhöhung über 10 Millionen US-Dollar ab | 4 | Investing.com Deutsch | ||
| 19.03. | REVIVA PHARMACEUTICALS HOLDINGS, INC. - 8-K, Current Report | 4 | SEC Filings | ||
| 19.03. | Reviva Pharmaceuticals prices $10M public offering at $1.50 | 3 | Investing.com | ||
| 19.03. | Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $10 Million Public Offering | 1 | GlobeNewswire (USA) | ||
| 18.03. | Reviva Pharmaceuticals announces proposed public offering | 1 | Seeking Alpha |
1 2 Weiter >>
39 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BAYER | 38,060 | +0,24 % | Bayer-Bildgebungs-Marker erreicht primäre Endpunkte in Phase-3-Studie | DJ Bayer-Bildgebungs-Marker erreicht primäre Endpunkte in Phase-3-Studie
DOW JONES--Bayer hat mit einem kürzlich zugekauften Bildgebungs-Marker für die Diagnose der kardialen Amyloidose namens... ► Artikel lesen | |
| NOVO NORDISK | 40,235 | +0,46 % | Mit guten Konzepten und Entspannung im Nahost-Konflikt voran! MustGrow, K+S, Evotec und Novo Nordisk im Fokus | Erstellt und veröffentlicht im Auftrag von MustGrow Biologics Corp. Was für eine Nachricht: Einigung zwischen USA und dem Iran - Märkte plus 2 % in nur 1 Minute! So schnell kann es gehen. Für Investoren... ► Artikel lesen | |
| ROCHE | 350,55 | +0,12 % | Roche stärkt KI-Diagnostik mit Kauf von PathAI für bis zu 1,05 Mrd USD | DJ Roche stärkt KI-Diagnostik mit Kauf von PathAI für bis zu 1,05 Mrd USD
Von Adria Calatayud
DOW JONES--Roche Holdings übernimmt PathAI für bis zu 1,05 Milliarden US-Dollar, um die auf Künstlicher... ► Artikel lesen | |
| VIATRIS | 14,734 | -0,71 % | Viatris Swings To Q1 Profit, Reaffirms FY26 Outlook | WASHINGTON (dpa-AFX) - Viatris Inc. (VTRS), a healthcare company, Thursday reported earnings for the first quarter compared to a loss for the same period last year. The results particularly... ► Artikel lesen | |
| GREEN THUMB INDUSTRIES | 6,580 | +1,54 % | Green Thumb expects Q2 revenue to be flat to down slightly while targeting about $80M in 2026 CapEx | ||
| TONIX PHARMACEUTICALS | 11,700 | -0,93 % | Tonix Pharmaceuticals Holding Corp.: Tonix Pharmaceuticals Reports First Quarter 2026 Financial Results and Operational Highlights | In the first full quarter since launch, 2,145 healthcare providers prescribed TONMYA, 3,588 patients initiated treatment, and ~5,400 prescriptions were filled Agreement signed in May with leading... ► Artikel lesen | |
| NEWRON PHARMACEUTICALS | 15,850 | +0,32 % | Newron Pharmaceuticals: Das Signal das die meisten Anleger noch nicht kennen - Was das für Ihr Depot bedeutet | ||
| FILANA THERAPEUTICS | 1,072 | +2,49 % | Filana Therapeutics, Inc.: Filana Therapeutics Reports Q1 2026 Financial Results and Business Update | AUSTIN, Texas, May 07, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA, "Filana Therapeutics", the "Company"), a biotechnology company currently focused on developing therapies for... ► Artikel lesen | |
| ORAMED PHARMACEUTICALS | 3,840 | -1,29 % | Lifeward Ltd.: Lifeward Successfully Closes on Strategic Partnership with Oramed | HUDSON, Mass. and YOKNEAM ILLIT, Israel, March 25, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology to transform... ► Artikel lesen | |
| COMPASS PATHWAYS | 9,450 | +1,07 % | Compass Pathfinder Limited: Compass Pathways Announces First Quarter 2026 Financial Results and Business Highlights | FDA granted Compass NDA rolling submission and review request, based on strength of Phase 3 data CNPV awarded for COMP360 in TRD, further accelerating momentum 26-week (Part B) data... ► Artikel lesen | |
| ACHIEVE LIFE SCIENCES | 4,920 | -3,53 % | Achieve Life Sciences Strengthens Board and Commercial Leadership with Three Senior Appointments from Team Previously at Verona Pharma | SEATTLE and VANCOUVER, British Columbia, May 12, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Achieve and the Company) (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused... ► Artikel lesen | |
| OPUS GENETICS | 4,320 | 0,00 % | Citizens cuts Opus Genetics stock price target on share dilution | ||
| AURINIA PHARMACEUTICALS | 13,570 | -0,84 % | Aurinia Pharmaceuticals Inc. - 10-Q, Quarterly Report | ||
| NRX PHARMACEUTICALS | 2,585 | +2,38 % | NRx Pharmaceuticals receives FDA clearance for depression trial | ||
| MINDWALK | 1,100 | +0,92 % | Highflyer der Zukunft - "Must Have" für ihr Biotech-Depot?! |
Das Unternehmen REVIVA PHARMACEUTICALS HOLDINGS INC kann der Branche Pharma zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,001 (-0,20 %) liegt der Kurs bei 0,351 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu REVIVA PHARMACEUTICALS HOLDINGS INC finden Sie auf Wallstreet Online.